CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals
CTD Holdings, Inc.
Sep. 13, 2018
Conference Brings the NPC community together for scientific exchanges and information sharing with NPC families
ALACHUA, Fla., Sept. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol® Cyclo™, at the Niemann-Pick UK (NPUK) 9th Interactive Workshop on Niemann-Pick Diseases and NPUK 25th Annual Family Conference. The conference will take place at the Wyboston Conference Centre, Bedfordshire, UK from September 21 to 23.
CTD's presentations will focus on the Phase I and Phase I/II intravenous clinical trials of Trappsol® Cyclo™, its proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of Niemann-Pick Disease Type C (NPC). Both the European Phase I/II and the U.S. Phase I trials are recruiting patients. The presentations will be made by Dr. Sharon Hrynkow, CTD’s Senior Vice President for Medical Affairs and by Dr. Julian Raiman, Consultant in Inherited Metabolic Disorders, Birmingham Women’s and Children’s Hospital NHS Foundation Trust, Birmingham, UK. Dr. Raiman is launching a site for pediatric patients at his institution.
The conference brings together patients, families, caregivers, scientists, and health professionals for the purposes of learning about advances in NPC clinical trials and providing opportunities for community learning, sharing and support.
CTD is pleased that several PIs responsible for sites in both ongoing clinical trials will participate at the conference this year. For the Phase I trial in the US, Dr. Caroline Hastings and Dr. Benny Liu, Principal Investigators at the UCSF Benioff Children’s Hospital Oakland will join the conference. For the Phase I/II trial in Europe and Israel, the following Principal Investigators will join: Dr. Orna Staretz-Chacham, Soroka Medical Center, Beer Sheva, Israel; Dr. Robin Lachmann, University College London, UK; and Dr. Raiman for the Birmingham site. Dr. Staretz-Chacham will also make a presentation during the Interactive Workshop on a recently accepted scientific paper for which she is lead author on the topic of lung involvement in NPC patients.
NPUK 9th Interactive Workshop on Niemann-Pick Diseases (participants are health professionals and scientists)
Date: Friday, September 21
Time & Title: Afternoon Session; NPC1 and Pulmonary Involvement, Dr. Orna Staretz-Chacham, Principal Investigator, CTD Phase II Intravenous clinical trial, Soroka Medical Center, Beersheeva, Israel.
Time & Title: Afternoon Session; Update on CTD’s Clinical Programs, Dr. Sharon Hrynkow, CTD Sr. VP for Medical Affairs.
NPUK 25th Annual Family Conference (participants are NPC patients and families, with updates on clinical trials provided by health professionals)
Date: Saturday, September 22
Time & Title: Morning Session; CTD’s Phase II Intravenous Trial of Trappsol® Cyclo™ for NP-C, Dr. Julian Raiman, Consultant, Birmingham Women’s and Children’s Hospital, Birmingham, UK
About CTD Holdings: CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company's website: www.ctd-holdings.com
Safe Harbor Statement: This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Investor/Media Contact: Sitrick and Company Wendy Tanaka (415) 369-8447 firstname.lastname@example.org
Thomas Mulligan (212) 573-6100, Ext. 395 email@example.com